However, positive selection techniques are less effective for CTC analysis of other solid tumors with low EpCAM expression, most notably non-small cell lung cancer and triple-negative (i.e., estrogen and progesterone receptor-negative, and HER2/neu-negative) breast cancer, which have a higher metastatic potential, and poorer survival outcomes compared to other breast cancer subtypes [11]. This evidence concerns the gene EPCAM and breast cancer.